Delivery Order SPE2DB20D3101-SPE2DB25FRRS9
- Not listed
- The Defense Logistics Agency (DLA) awarded a $12,636.36 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen injections on August 29, 2025, with a completion date of September 2, 2025. This delivery order represents a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The award was competitively awarded with no set-aside designation and...
- The Defense Logistics Agency awarded a $14,216.37 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 ml pen injections on July 30, 2025, with completion targeted for July 31, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $10,016.78 delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections. This firm fixed price contract, with an ultimate completion date of September 8, 2025, represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. The pharmaceutical product will be delivered to AmerisourceBergen's corporate...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors with a contract value of $15,251.60. This firm fixed-price delivery order, which is not set-aside and was competitively awarded, is scheduled for completion by August 12, 2025, with the place of performance located in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order valued at $13,836.67 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pens on August 18, 2025, with an ultimate completion date of August 19, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a $16,410.40 delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 mL pen injectors on September 24, 2025, with completion scheduled for September 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a child order under AmerisourceBergen's larger pharmaceutical supply contract vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors valued at $3,349.68 under a firm fixed price contract. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The pharmaceutical distributor will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 29, 2025, for the supply of Zepbound 5 mg/0.5 mL pens with a ceiling value of $13,460.35. This firm fixed-price delivery order is non-competitive and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The performance location is AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $12,539.80 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on July 31, 2025. This firm fixed-price, competitively awarded delivery order will be fulfilled from the vendor's Conshohocken, Pennsylvania facility, with an ultimate completion date of August 1, 2025. The contract carries no set-aside designation and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on May 2, 2025, for the supply of Zepbound 2.5 mg/0.5 ml pen injections. This competitively awarded, non-set-aside contract has a ceiling value of $10,683.61 with a firm fixed price structure and is scheduled for completion by May 5, 2025. The award will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRRS9Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injections with a ceiling value of $1,143.87. This competitively awarded, firm fixed-price delivery order is classified as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 5, 2025. This delivery order exemplifies AmerisourceBergen's role as a critical pharmaceutical distributor within the federal medical supply chain, particularly supporting military and veteran healthcare systems. As the prime contractor on the DLA Troop Support Medical IDC, AmerisourceBergen supplies a comprehensive portfolio of pharmaceutical products and medical commodities across multiple therapeutic areas. The award of this Zepbound order demonstrates the company's continued capability to fulfill federal procurement requirements for specialty medications on a competitively awarded basis without set-aside designation.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 8/4/25 |